Updated Odronextamab Data from Relapsed/Refractory Diffuse - GlobeNewswire
Phase 2 trial results for odronextamab showed a 52% ORR and 31% CR in DLBCL patients, with durable responses. Phase 1 data indicated a 48% ORR and 30% CR post-CAR-T progression. ctDNA negativity linked to longer PFS. Odronextamab is under FDA and EMA review for R/R DLBCL and FL.
Reference News
Updated Odronextamab Data from Relapsed/Refractory Diffuse - GlobeNewswire
Phase 2 trial results for odronextamab showed a 52% ORR and 31% CR in DLBCL patients, with durable responses. Phase 1 data indicated a 48% ORR and 30% CR post-CAR-T progression. ctDNA negativity linked to longer PFS. Odronextamab is under FDA and EMA review for R/R DLBCL and FL.